MT
Maxymune Therapeutics, Inc.
SEC filingBiotechnology · Los Altos, CA
Amount raised$2.7Msold at filing
Total offering$4.5M$1.8M still open
Investors in the raise15count reported to the SEC
FiledJun 3, 2026first sale Feb 11, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Tatjana NarandaExecutive Officer, Director
Neil SolomonsDirector
Gordon RingoldExecutive Officer, Director
Executive officers, directors and promoters as listed on the Form D.